高雄市生物科技發展協會|http://www.khba.org.tw
會員登入
記住帳號 自動登入
會員名錄
各式辦法
下載專區
留言板
您目前的位置:首頁 / 活動與新訊
Without Action, Drug-Resistant “Superbugs” Will Kill Millions in Europe
活動日期:2018.11.13
2018.11.13  

Without Action, Drug-Resistant “Superbugs” Will Kill Millions in Europe
https://www.the-scientist.com/news-opinion/without-action--drug-resistant-superbugs-will-kill-millions-in-europe-65058

Antibiotic-resistant infections could kill 2.4 million people in Europe, North America, and Australia by 2050 without further action to combat the infections, according to a report released yesterday (November 7) by the Organization for Economic Cooperation and Development. But the report also says that short-term investments by governments could push back against diseases and save money in the long run.
“Drug-resistant superbugs are on the rise worldwide and represent a fundamental threat to global health and development. This report provides yet further evidence that investing to tackle the problem now will save lives and deliver big payoffs in the future,” Tim Jinks, head of the Wellcome Trust’s drug-resistant infections priority program, tells The Guardian.
Among the 36 member countries of the Organization for Economic Cooperation and Development (OECD), resistance to second- and third-line antibiotics—the most advanced drugs available to treat infections after initial rounds fail—is expected to be 70 percent higher in 2030 than it was in 2005, according to a press release.
The report suggests that to combat the superbug rise, governments use tactics such as promoting hygiene practices, such as hand washing, and ending over-prescribing of antibiotics. For $2 per person per year, three out of four deaths from superbugs could be averted, according to the release. 
“Investing $2 per person per year in a comprehensive package encompassing public health measures would avoid about 47,000 deaths per year in OECD countries,” Michele Cecchini of the OECD’s health division tells CNBC. “The public health package could pay for itself within just one year and end up by saving $4.8 billion of dollars per year in OECD countries.”

 

共有310筆資料 頁數: 第2頁(共16頁)
編號 標題 新增日期
1 施貴寶Opdivo(nivolumab)+Yervoy(ipilimumab)用於晚期肝癌一線.. 2024.03.26
2 ‘Damning’ FDA inspection report undermines positive tria.. 2024.03.19
3 2024年最值得期待的十大新藥(二之一):思覺失調、阿茲海默症、.. 2024.03.19
4 Neutrophils: Unraveling their multifaceted roles in inflam.. 2024.03.14
5 諾和諾德與加州生技公司Neomorph簽訂14.6億美元協議,開發心臟.. 2024.03.14
6 Scientists discover the Achilles heel of chemotherapy-resi.. 2024.03.06
7 New research shows promise for urine-based test to detect .. 2024.03.06
8 New method traces primed resistance in cancer via sister c.. 2024.03.06
9 高靈敏度、低偽陽性、無不適感,「正子乳房斷層攝影」有望改.. 2024.03.06
10 高療效卻有高風險副作用!再生元的骨髓瘤雙特異性抗體linvoselt.. 2024.03.06
11 Turning Off Metastasis in Breast Cancer 2024.02.22
12 瞄準減肥市場!再生元(Regeneron)開發單株抗體,降低GLP-1受體.. 2024.02.22
13 Machine learning unlocks personalized approach to early ov.. 2024.02.15
14 開源節流!!羅氏退回Repare抗癌口服候選新藥camonsertib之合作R.. 2024.02.15
15 Gut microbiome plays a role in immune response to mRNA COV.. 2024.01.23
16 《Blood》細菌會抵消癌症治療的效果—20240118 2024.01.23
17 Epigenetic Changes Drive Cancer 2024.01.03
18 類風濕性關節炎惡化幫兇,最新研究揪出關鍵蛋白質 2024.01.03
19 Study explores the intricate gut-brain-liver connection an.. 2023.12.21
20 20年首見!Arcutis脂漏性皮膚炎泡沫軟膏獲美批准 2023.12.21
上一頁  1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16  下一頁
版權所有©2006 高雄市生物科技發展協會 所有文字、資料禁止轉用
地址:高雄市中正一路120號14樓之3 TEL:(07)591-9569 / FAX:(07)591-9018 / e-mail: khba.tw@gmail.com
累積進站人數:2897303